Pathophysiology of bullous auto-immune basement membrane zone dermatosis;Physiopathologie des dermatoses bulleuses auto-immunes de la jonction dermo-epidermique

Annales de Dermatologie et de Venereologie

Volumn 125, Issue 11, 1998, Pages 817-823

  Salmon Ehr, V ^a   Bernard, Ph ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; BASEMENT MEMBRANE; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; MICE; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS;

EID: 0031793353     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Bernard P, Bedane C. La jonction dermo-épidermique : données actuelles. In: biologie de la peau humaine, p151-67, 1997, Ed INSERM.
2. Borradori L, Sonnenberg A. Hemidesmosomes : role in adhesion, signaling and human diseases. Curr Opin Cell Biol 1996;8:647-56.
3. Stanley JR, Woodley DT, Katz SI. Identification and partial characterization of pemphigoid antigen extracted from normal human skin. J Invest Dermatol 1984;82:108-11.
4. Elgart GW, Stanley JR. Cloning of the 5' mRNA for the 230-kD bullous pemphigoid antigen by rapid amplification of cDNA ends. J Invest Dermatol 1993;101:244-6.
5. Bernard P, Prost C, Durepaire N, Basset-Seguin N, Didierjean L, Saurai JH. The major cicatricial pemphigoid antigene is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. J Invest Dermatol 1992;99:174-9.
6. Giudice GJ, Squiquera HL, Elias PM, Diaz LA. Identification of two collagen domains within the bullous pemphigoid. BP180. J Clin Invest 1991;87:734-8.
7. Hopkinson SB, Baker SE, Jones JCR. Molecular genetic studies of a human epidermal autoantigen (the 180-kD bullous pemphigoid antigen/BP180): Identification of functionally important sequences within the BP180 molecule and evidence for an interaction between BP180 and α6 integrin. J Cell Biol 1995;130:117-25.
8. Balding S, Prost C, Diaz LA, Bernard P, Bedane C, Aberdam D, Giudice GJ. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996;106:141-6.
9. Kirstchig G, Marinkovich MP, Burgerson RE, Yancey KB. Antibasement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the α subunit of laminin 5. J Invest Dermatol 1995;105:543-8.
10. Masunaga T, Shimizu H, Yancey KB, Nishikawa T. Altered ultrastructural localization of the C-terminus of bullous pemphigoid antigen 2 (BPAG2) in human skin lacking laminin 5. J Invest Dermatol 1998;110:508.
11. Keene DR, Sakai LY, Lunstrum GP, Morris NP, Burgeson RE. Type VII collagen formes an extended network of anchoring fibrils. J Cell Biol 1987;104:611-21.
12. Lapiere JC, Woodley DT, Parente MG, Iwasaki T, Wynn KC, Christiano AM, Uitto J. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993;92:1831-9.
13. Rico MJ, Streilein RD, Hall RP. Peripheral blood mononuclear cells from patients with bullous pemphigoid have an increased frequency of response to synthetic peptides encoded by BPAG1. J Invest Dermatol 1994;103:73-7.
14. Jordon RE, Kawana S, Fritz KA. Immunopathologic mechanisms in pemphigus and bullous pemphigoid. J Invest Dermatol 1985;85:72-8.
15. Suzuki M, Harada S, Yaoita Y. Purification of bullous pemphigoid IgG subclasses and their capability for complement fixation. Acta Derm Venereol 1992;72:245-9.
16. Dahl MV, Falk RJ, Carpenter R, Michael AF. Deposition of the membrane attack complex of complement in bullous pemphigoid. J Invest Dermatol 1984;82:132-5.
17. Dubertret L, Bertaux B, Fosse M, Touraine R. Cellular events leading to blister formation in bullous pemphigoid. Br J Dermatol 1980;104:615-24.
18. Delaporte E, Dubost-Brama A, Ghohestani R, Nicolas JF, Neyrinck JL, Bergoend H, Janin A, Capron M. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol 1996;157:3642-7.
19. Stähle-Bäckahl M, Inoue M, Giudice GJ, Parks WC. 92 kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180 kD bullous pemphigoid autoantigen. J Clin Invest 1994;93:2022-30.
20. Gammon WR, Merritt CC, Lewis DM, Sams WM, Carlo JR, Wheeler CE. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol 1982;78:285-90.
21. Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995;95:1539-44.
22. Kuwabara H, McVittie E, Hunter JAA, Uda H, Yamauchi A, Sakamoto H. Expression of mRNA of tumor necrosis factor a and interleukin-6 in bullous pemphigoid skin. Eur J Dermatol 1996;6:300-30.
23. Schmidt E, Ambach A, Bastian B, Bröcker EB, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. J Am Acad Dermatol 1996;34:310-2.
24. Brown LF, Harrist TJ, Yeo KT, Stähles-Bäckdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol 1995; 104:744-9.
25. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113:1043-7.
26. Borradori L, Cadwell JB, Briggaman RA, Burr CE, Gammon WR, James WD, Yancey KB. Passive transfert of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Arch Dermatol 1995;131:590-5.
27. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993;92:2480-8.
28. Katz A, Minta JO, Toole JWP, Medwidsky W. Immunopathologic study in herpes gestationis in mother and child. Arch Dermatol 1977;113:1069-72.
29. Nestor MS, Cochran AJ, Ahmed AR. Mononuclear cell infiltrates in bullous disease. J Invest Dermatol 1987;88:172-5.
30. Zillikens D, Ambach A, Schuessler M, Dummer R, Hartmann AA, Bure G. The interleukin-2 receptor in lesions and serum of bullous pemphigoid. Arch Dermatol Res 1992;284:141-5.
31. Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996;288:353-7.
32. Venning VA, Allen J, Aplin JD, Kirtsching G, Wojnarowska F. The distribution of α6β4 integrins in lesional and non-lesional skin in bullous pemphigoid. Br J Dermatol 1992;127:103-11.
33. Taylor G, Venning V, Wojnarowska F, Welch K. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 1993;29:181-4.
34. Delgado JC, Turbay D, Yunis JJ, Morton ED, Bhol K, Norman R, Alper CA, Good RA, Ahmed R. A common major histocompatibility complex class II allele HLA-DQBI 0301 is present in clinical variants of pemphigoid. Proc Nat Acad Sci USA 1996;93:8569-71.
35. Masouyé I, Schmied E, Didierjean L, Abba Z, Saurat JH. Bullous pemphigoid and multiple sclerosis: more than a coincidence ? J Am Acad Dermatol 1989; 21:63-8.
36. Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C, Salagnac V, Lok C, Roujeau JC. Drugs associated with bullous pemphigoid. Arch Dermatol 1996;132:272-6.
37. Claudy AL. La pemphigoïde gestationis: un modèle unique d'autoimmunité spécifique d'organe. Ann Dermatol Venereol 1991;118:323-7.